Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of CN1 in Advanced Solid Tumors or B-cell Lymphoma
NCT04418141Phase 1Completed
- Sponsor
- Curon Biopharmaceutical
- Start
- Jul 2020
- Primary completion
- Oct 2021
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of CN201 in solid tumor and B cell lymphoma, sponsored by Curon Biopharmaceutical. Primary endpoints: Dose-Limiting Toxicity at 21 days, Maximum Tolerated Dose at 21 days and 1 more. Started Jul 2020; status: completed.
02
Drugs
CN201
03
Conditions
solid tumorB cell lymphoma
Beyond the preview
Go deeper on NCT04418141.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04418141.